UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Vascular disrupting agents in clinical development

British journal of cancer, 2007-04, Vol.96 (8), p.1159-1165

2007

Volltextzugriff (PDF)

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

British journal of cancer, 2014-04, Vol.110 (9), p.2170-2177

2014

Volltextzugriff (PDF)

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

European Journal of Cancer, 2009-07, Vol.45 (10), p.1764-1772

2009

Volltextzugriff (PDF)

Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment

Annals of surgical oncology, 2015-07, Vol.22 (7), p.2401-2407

2015

Volltextzugriff (PDF)

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

Cancer chemotherapy and pharmacology, 2015-02, Vol.75 (2), p.365-371

2015

Volltextzugriff (PDF)

The spliceosome as target for anticancer treatment

British journal of cancer, 2009-01, Vol.100 (2), p.228-232

2009

Volltextzugriff (PDF)

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study

British journal of cancer, 2014-02, Vol.110 (4), p.888-893

2014

Volltextzugriff (PDF)

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics

The pharmacogenomics journal, 2016-11, Vol.16 (6), p.519-524

2016

Volltextzugriff (PDF)

A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome

Radiotherapy and oncology, 2021-02, Vol.155, p.232-236

2021

Volltextzugriff (PDF)

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study

British journal of cancer, 2007-05, Vol.96 (9), p.1348-1352

2007

Volltextzugriff (PDF)

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Annals of oncology, 2006-08, Vol.17 (8), p.1320-1327

2006

Volltextzugriff (PDF)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

British journal of cancer, 2004-01, Vol.90 (1), p.1-7

ESKENS, Falm

2004

Volltextzugriff (PDF)

Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib

Annals of oncology, 2018-10, Vol.29, p.viii584-viii584

2018

Volltextzugriff (PDF)

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Annals of oncology, 2018-10, Vol.29, p.viii422-viii422

2018

Volltextzugriff (PDF)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

British journal of cancer, 2004-01, Vol.90 (1), p.1-7

Eskens, F A L M

2004

Volltextzugriff (PDF)

Systemic treatment in hepatocellular carcinoma; 'A small step for man...'

Netherlands journal of medicine, 2009-03, Vol.67 (3), p.86-90

2009

Volltextzugriff (PDF)

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

British journal of cancer, 2010-10, Vol.103 (9), p.1362-1368

2010

Volltextzugriff (PDF)

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus

Annals of oncology, 2003-08, Vol.14 (8), p.1253-1257

2003

Volltextzugriff (PDF)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

British journal of cancer, 2010-09, Vol.103 (7), p.987-992

2010

Volltextzugriff (PDF)

Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy

Netherlands journal of medicine, 2014-07, Vol.72 (6), p.299-304

2014

Volltextzugriff (PDF)

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

European journal of cancer (1990), 2006-03, Vol.42 (4), p.467-472

2006

Volltextzugriff (PDF)

Temozolomide chemotherapy in recurrent oligodendroglioma

Neurology, 2001-07, Vol.57 (2), p.340-342

2001

Volltextzugriff (PDF)

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

European journal of cancer (1990), 2002-11, Vol.38 (17), p.2272-2278

2002

Volltextzugriff (PDF)

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

British journal of cancer, 2003-12, Vol.89 (11), p.2045-2050

2003

Volltextzugriff (PDF)

Tivozanib: a new treatment option for renal cell carcinoma

Drugs of Today, 2017-11, Vol.53 (11), p.609-618

2017

Volltextzugriff (PDF)

1 – 25 von 130

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(120)

Publikationsform

Artikel
(130)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(55)
Science & Technology
(55)
Humans
(54)
Oncology
(38)
Female
(35)
Male
(34)
Middle Aged
(34)
Aged
(30)
Biological And Medical Sciences
(30)
Medical Sciences
(29)
Neoplasms - Drug Therapy
(27)
Adult
(26)
Tumors
(22)
Chemotherapy
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Pharmacokinetics
(14)
Pharmacology. Drug Treatments
(14)
Antineoplastic Agents
(13)
Dose-Response Relationship, Drug
(12)
Treatment Outcome
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Vascular disrupting agents in clinical development

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

The spliceosome as target for anticancer treatment

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics

A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Systemic treatment in hepatocellular carcinoma; 'A small step for man...'

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

Temozolomide chemotherapy in recurrent oligodendroglioma

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

Tivozanib: a new treatment option for renal cell carcinoma

Suchergebnisse filtern